Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Modulation of Regulatory T-Cell and B-Cell Lymphocytes for the Treatment of Autoimmune and Other Disease Indications

Posted Sep 27 2012 8:00pm

Description of Invention:
A method of modulating the immune response by affecting the activity of the regulatory lymphocytes through targeting of the Hepatitis A Virus receptor 1 (HAVCR1) receptor. This methodology can be developed for the treatment of autoimmune diseases, allergies, prevention of transplant rejection, and incorporated into therapeutic strategies for cancer.

Regulatory lymphocytes, such as regulatory T-cells (Tregs) and B-cells (Bregs), play a significant role in suppressing and controlling immune responses to antigens, including allergens and self-antigens that induce autoimmune diseases. The Tregs and Bregs also control the immune responses to microbial pathogens thereby limiting excessive damage to tissue. HAVCR1 is expressed on these regulatory lymphocytes and functions as a master regulator of these cells.

Applications:
  • Treatment of Autoimmune Diseases
  • Treatment of Allergies
  • Prevention of Rejection of Allogenic Transplants
  • Cancer Therapy
  • Immunotherapies
  • Stimulate Response to Vaccines (adjuvant)


Advantages:
Can be used to target multiple disease states.

Development Status:
  • Early-stage
  • Pre-clinical
  • In vitro data available


Inventors:
Gerardo Kaplan (FDA)
Mohanraj Manangeeswaran (FDA)
Jerome Jacques (FDA)
Krishnamurthy Konduru (FDA)


Patent Status:
HHS, Reference No. E-095-2012/0
US, Application No. 61/611,437 filed 15 Mar 2012


Related Technologies:
US, Patent No. 5,622,861, Issued 22 Apr 1997, Reference No. E-150-1994/0 (Hepatitis A Virus Receptor)


Relevant Publication:
  1. Manangeeswaran M, et al. [ PMID 22430395 ]


Collaborative Research Opportunity:
The Center for Biologics Evaluation and Research, Laboratory of Emerging Pathogens, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize targeting of HAVCR1 to control Treg and Breg function in human diseases. For collaboration opportunities, please contact Gerardo Kaplan at gerardo.kaplan@fda.hhs.gov .


For Licensing Information Please Contact:
Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: changke@mail.nih.gov
Phone: 301-435-5018
Fax: 301-402-0220


Ref No: 2480

Updated: 09/2012

Post a comment
Write a comment: